About lanadelumab
Monoclonal antibody; kallikrein inhibitor
Used for
- Prevents attacks of hereditary angioedema (HAE) in adults and children aged 2 years or older.
Usual adult dose
For adults and adolescents aged 12 years or older: 300 mg under the skin every 2 weeks. Some well-controlled patients may use every 4 weeks.
Usual dose in children
Ages 2–5 years: 150 mg every 4 weeks. Ages 6–11 years: 150 mg every 2 weeks; some well-controlled patients may use every 4 weeks.
Common side effects
- Injection-site reactions
- Upper respiratory infections
- Headache
- Dizziness or rash
Important warnings
- Not for treating an acute HAE attack; keep prescribed rescue treatment available.
- Severe allergic reactions, including anaphylaxis, are possible.
- May affect some blood clotting laboratory test results.
Pregnancy
Human pregnancy information is limited; use only when a healthcare professional considers it necessary.
Breastfeeding
It is unknown whether lanadelumab passes into breast milk; discuss potential benefits and risks with a healthcare professional.
Interactions
- No important drug interactions are established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.